Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results

August 9, 2016 4:06 PM EDT

Total Revenues of $186.5 MillionAdjusted EPS of $0.36 and Diluted EPS of $0.32Company Issues Fiscal First-Quarter 2017 and Fiscal Year 2017 Financial Guidance  

SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal fourth-quarter 2016, provided an update on recent business highlights and provided fiscal first-quarter 2017 and fiscal year 2017 financial guidance. 

"Fourth-quarter performance met our expectations, and we continue to make substantial progress on advancing our product portfolio and growing Myriad into a... More